Article
The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
Oncotarget - 2 Aug 2016
Raza Umar, Saatci Özge, Uhlmann Stefan, Ansari Suhail A, Eyüpoğlu Erol, Yurdusev Emre, Mutlu Merve, Ersan Pelin Gülizar, Altundağ Mustafa Kadri, Zhang Jitao David, Doğan Hayriye Tatlı, Güler Gülnur, Şahin Özgür
Abstract excerpt
Tumor cells develop drug resistance which leads to recurrence and distant metastasis. MicroRNAs are key regulators of tumor pathogenesis; however, little is known whether they can sensitize cells and block metastasis simultaneously. Here, we report miR-644a as a novel inhibitor of both cell survival and EMT whereby acting as pleiotropic therapy-sensitizer in breast cancer. We showed that both miR-644a expression...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.